CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean C. Tien, Arul M. Chinnaiyan, Ke Ding et al.|Cell Reports Medicine|2024Cited by 28
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Arul M. Chinnaiyan, Yuanyuan Qiao et al.|Proceedings of the National Academy of Sciences|2024Cited by 22
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Arul M. Chinnaiyan, Xuhong Cao et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 4
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean C. Tien, Arul M. Chinnaiyan, Ke Ding et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 1